GD2CART for Osteosarcoma or Neuroblastoma

AddtoAny
Share:

WATCH THIS PAGE

Subscribe to be notified of changes or updates to this page.

2 + 17 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
This study enrolls patients that have been diagnosed with osteosarcoma or neuroblastoma that has come back (relapsed) or has not responded to standard treatments (refractory). This study involves an investigational cellular therapy called GD2CART. The study will be testing different doses of the study drug to find the safest dose.

Who Do I Contact?

If you are interested in participating in the study or want to learn more please contact our study team at CancerTrials [at] chop.edu or 267-425-5544.

ClinicalTrials.gov Identifier

NCT04539366

View full trial information on ClinicalTrials.gov

Eligibility & Criteria

IRB #:
22-020029
Official Title:
PED*CITN*02: GD2-CAR PERSIST: Production and Engineering of GD2-Targeted, Receptor Modified T Cells (GD2CART) for Osteosarcoma or Neuroblastoma to Increase Systemic Tumor Exposure
Study Phase:
Phase I
Eligible Age Range:
1 - 40 Years
Gender:
All
Study Categories:

Visit Criteria

Participants in this research will:

  • Have an electrocardiogram (ECG) and echocardiogram (ECHO) before receiving the cellular therapy
  • Undergo apheresis to remove white blood cells (called T Cells) from their blood
  • Receive the cellular therapy called GD2CART via infusion. This is manufactured from participant's T Cells.
  • Complete frequent clinic visits at CHOP
  • Have research blood tests
  • Have extra or leftover tissue collected if they have a biopsy as part of regular cancer care